Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing novel therapies for ocular and rare diseases. They generate revenue primarily through collaborations, licensing agreements, and milestone payments. Founded in 2006 and headquartered in Redwood City, California, Adverum has made significant strides in gene therapy, particularly with their lead product candidate, ADVM-022, aimed at treating wet age-related macular degeneration. The company’s innovative approach leverages proprietary adeno-associated virus (AAV) vector technologies to deliver therapeutic genes, positioning them as a leader in the gene therapy space.

Recent Posts by Adverum Biotechnologies

1-3 of 3